Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus Trastuzumab in HER2+ Breast Cancer
NCT05255523Phase 2Unknown
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label trial of pyrotinib in HER2-positive breast cancer, sponsored by Fujian Medical University Union Hospital. Primary endpoint: Incidence of first progression with brain metastases at 24 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05255523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255523.